Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Frequently asked questions
What sector does Galectin Therapeutics Inc (GALT) operate in?
Galectin Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Galectin Therapeutics Inc (GALT) current stock price?
As of the latest data, Galectin Therapeutics Inc stock price is $3.69, with a previous close of $3.73. Galectin Therapeutics Inc lost -$0.05 in the last trading session, representing a -1.21% loss.
What is Galectin Therapeutics Inc (GALT) current market capitalization?
Galectin Therapeutics Inc market cap is approximately 371.63 million.
What is Galectin Therapeutics Inc (GALT) Earnings Per Share (EPS)?
The trailing EPS is -$0.43, and the forward EPS is -$0.23.
What is Galectin Therapeutics Inc (GALT) EBITDA?
Galectin Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -827.00 thousand.
Does Galectin Therapeutics Inc (GALT) pay dividends?
No. Galectin Therapeutics Inc does not pay a dividend.
What is Galectin Therapeutics Inc (GALT) beta (volatility) score?
Galectin Therapeutics Inc has a beta of 0.347, indicating lower volatility than the overall market.
